Published in Public Health Genomics on March 12, 2015
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 13.44
Macrophage activation and polarization. Front Biosci (2008) 11.17
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 9.82
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
UK health performance: findings of the Global Burden of Disease Study 2010. Lancet (2013) 6.11
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
Macrophage polarization in tumour progression. Semin Cancer Biol (2008) 4.62
The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol (2007) 3.95
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
Transcriptional profiling reveals complex regulation of the monocyte IL-1 beta system by IL-13. J Immunol (2005) 3.87
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol (2005) 3.48
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol (2003) 3.41
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev (2008) 3.33
Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A (2009) 3.27
The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol (2004) 3.21
Cancer: Inflaming metastasis. Nature (2009) 3.09
Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med (2014) 3.08
Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature (2002) 3.01
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol (2011) 2.99
Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med (2010) 2.94
Cancer related inflammation: the macrophage connection. Cancer Lett (2008) 2.88
Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. BMJ (2010) 2.77
p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res (2006) 2.76
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol (2005) 2.75
The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med (2007) 2.71
An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol (2010) 2.71
Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol (2010) 2.60
The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood (2003) 2.57
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol (2011) 2.45
[Cause-specific mortality in an area of Campania with numerous waste disposal sites]. Epidemiol Prev (2005) 2.37
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res (2004) 2.31
Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2004) 2.31
Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol (2003) 2.24
Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation (2008) 2.18
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood (2013) 2.14
Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation (2009) 2.11
Cerebral palsy and intrauterine growth in single births: European collaborative study. Lancet (2003) 2.11
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol (2010) 2.07
Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A (2004) 2.06
The prevalence of congenital anomalies in Europe. Adv Exp Med Biol (2010) 1.99
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron (2010) 1.96
Pathways connecting inflammation and cancer. Curr Opin Genet Dev (2008) 1.95
Congenital heart defects in Europe: prevalence and perinatal mortality, 2000 to 2005. Circulation (2011) 1.95
Orchestration of metabolism by macrophages. Cell Metab (2012) 1.92
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
Tumor associated macrophages and neutrophils in cancer. Immunobiology (2013) 1.87
Chemokines and chemokine receptors: an overview. Front Biosci (Landmark Ed) (2009) 1.87
Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity (2005) 1.86
Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res (2002) 1.86
Cytokines as a key component of cancer-related inflammation. Cytokine (2008) 1.85
Cancer: inflammation by remote control. Nature (2005) 1.85
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2011) 1.84
Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.82
IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect (2004) 1.82
IL-1 family nomenclature. Nat Immunol (2010) 1.79
Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 1.78
Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol (2008) 1.76
Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med (2010) 1.75
Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol (2007) 1.75
Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol (2013) 1.74
Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol (2006) 1.72
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development (2004) 1.68
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res (2010) 1.68
Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol (2003) 1.67
Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol (2013) 1.67
Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A (2004) 1.66
Congenital anomalies in children with cerebral palsy: a population-based record linkage study. Dev Med Child Neurol (2009) 1.63
Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol (2006) 1.63
Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation (2006) 1.58
The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev (2009) 1.57
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem (2002) 1.55
Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med (2005) 1.54
Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res (2007) 1.54
Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol (2013) 1.54
Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol (2002) 1.52
Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J Immunol (2003) 1.52
Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res (2010) 1.51
Twenty-year trends in the prevalence of Down syndrome and other trisomies in Europe: impact of maternal age and prenatal screening. Eur J Hum Genet (2012) 1.51